Drug intelligence / Profile preview

escitalopram + paroxetine + sertraline

Development stage
Discontinued
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of three selective serotonin reuptake inhibitors (SSRIs): escitalopram, paroxetine, and sertraline. Each of these medications works by inhibiting the reuptake of serotonin in the brain, though they have different pharmacological profiles and side effect patterns. Escitalopram is an allosteric serotonin reuptake inhibitor (ASRI) with well-documented allosteric properties at the serotonin transporter (SERT). Paroxetine has cholinergic muscarinic antagonism and potent inhibition of CYP2D6. Sertraline has dopamine transporter (DAT) inhibitory properties and moderate drug-drug interaction issues. These medications are typically prescribed individually rather than in combination for treating depression, anxiety disorders, and other mood disorders.

02

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on escitalopram + paroxetine + sertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + paroxetine + sertraline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call